News
GlobalData on MSN21h
Novartis’ Cosentyx shows no benefit in Phase III GCA trialNovartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback